Furthermore, while the neural classification has been removed, further advances in glioma genetic characterization have allowed updating GBM classification as isocitrate dehydrogenase (IDH)-wild type or IDH-mutant, which roughly correspond to primary and secondary GBM, respectively [52]. The gene discussed is IDH1; the disease is central nervous system cancer.